All In Biotech

Investigational drug · Phase 3

Zilebesiran

Also called: ALN-AGT01

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

2 still active

All registered trials

7

Any phase or sponsor naming "Zilebesiran"

First trial start

2024

Feb 29, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zilebesiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hypertension
  • High Cardiovascular Risk
  • High Risk Cardiovascular Disease
  • Mild to Moderate Hypertension

Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Zilebesiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 63 on PubMed

Also in development for Hypertension

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • CagriSemaCagrilintide B and Semaglutide IPhase 36 trials

    Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension

  • lorundrostatPhase 35 trials

    Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease

  • VCT220CX11Phase 35 trials

    Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension

  • VicadrostatBI 690517Phase 35 trials

    Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • DWC202314Phase 32 trials

    Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension

  • DWC202314PPhase 32 trials

    Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Alnylam Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.